TJP1 and Miyoshi myopathy: Recently, Orlowski and colleagues reported that relative resistance to bortezomib and carfilzomib in some MM cell lines was associated with decreased expression of the tight junction protein 1 gene TJP1 (also known as zonula occludens 1, ZO-1) and they proposed that high TJP1 expression might be used as a biomarker of proteasome inhibitor sensitivity in the clinic [10].